NCT01834066

Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Muscular Dystrophy.

Safety and Efficacy of Bone Marrow Autologous Cells in Muscular Dystrophy. It is Self Funded (Patients' Own Funding) Clinical Trial

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Chaitanya Hospital, Pune · Academic / Other
• Sex: All
• Age: 6 Years – 25 Years
• Healthy volunteers: Accepted

Summary

This Study is single arm, single centre trial to check the safety and efficacy of Bone Marrow derived autologous cell(100 million per dose) for the patient with Duchenne Muscular Dystrophy.

Detailed description

Muscular dystrophy is a group of inherited disorders that involve muscle weakness and loss of muscle tissue, which get worse over time. Duchenne muscular dystrophy is caused by a defective gene for dystrophin (a protein in the muscles). However, it often occurs in people without a known family history of the condition. slowly progress diseases.it causes Muscle weaknesses, Difficulty with motor skills ,Progressive difficulty walking.Breathing difficulties and heart disease,Frequent falls,weak limbs,lose motor Function.Begins in the legs and pelvis, but also occurs less severely in the arms, neck, and other areas of the body.Trouble getting up from a lying position or climbing stairs.

Conditions

• Muscular Dystrophy
• Duchenne Muscular Dystrophy,

Interventions

Type	Name	Description
BIOLOGICAL	Stem Cell	Intralesional transfer of Autologous Stem cell (MNCs) per dose. 6 doses in 3 months

Timeline

• Start date: 2014-09-01
• Primary completion: 2016-11-01
• Completion: 2016-12-01
• First posted: 2013-04-17
• Last updated: 2014-09-17

Locations

1 site across 1 country: India